- Q1 2024 Photocure ASA Earnings Call TranscriptMay 15, 2024$5.95Earnings
- Q4 2023 Photocure ASA Earnings Call TranscriptFeb 21, 2024$6.5Earnings
- Q3 2023 Photocure ASA Earnings Call TranscriptNov 08, 2023$5Earnings
- Q2 2023 Photocure ASA Earnings Call TranscriptAug 09, 2023$4.75Earnings
- Q1 2023 Photocure ASA Earnings Call TranscriptMay 10, 2023$10.85Earnings
- Q4 2022 Photocure ASA Earnings Call TranscriptFeb 23, 2023$10.85Earnings
- Q3 2022 Photocure ASA Earnings Call TranscriptNov 02, 2022$10.13Earnings
- Q2 2022 Photocure ASA Earnings Presentation TranscriptAug 10, 2022
- Q1 2022 Photocure ASA Earnings Presentation TranscriptMay 11, 2022
- Photocure ASA at Needham Healthcare Conference (Virtual) TranscriptApr 14, 2022
- Q4 2021 Photocure ASA Earnings Presentation TranscriptFeb 23, 2022
- Q3 2021 Photocure ASA Earnings Call TranscriptNov 17, 2021$12.25Earnings
- Q2 2021 Photocure ASA Earnings Call TranscriptAug 11, 2021$15.87Earnings
- Photocure ASA Annual Shareholders Meeting TranscriptMay 20, 2021
- Q1 2021 Photocure ASA Earnings Presentation TranscriptMay 19, 2021
- Q4 2020 Photocure ASA Earnings Call TranscriptMar 03, 2021$14Earnings
- Q3 2020 Photocure ASA Earnings Call TranscriptNov 10, 2020$8.01Earnings
- Q2 2020 Photocure ASA Earnings Call TranscriptAug 18, 2020$7.15Earnings
- Photocure ASA Annual Shareholders Meeting TranscriptJun 10, 2020
- Q1 2020 Photocure ASA Earnings Call TranscriptMay 07, 2020$6.8Earnings
- Q4 2019 Photocure ASA Earnings Call TranscriptFeb 27, 2020$9.75Earnings
- Q3 2019 Photocure ASA Earnings Call TranscriptNov 07, 2019$6.35Earnings
- Q2 2019 Photocure ASA Earnings Call TranscriptAug 07, 2019$6.5Earnings
- Q1 2019 Photocure ASA Earnings Call TranscriptMay 14, 2019$4.85Earnings
Q2 2021 Photocure ASA Earnings Call Transcript
All right. Well, welcome. This is Dan Schneider, President and CEO of Photocure. With me today is Erik Dahl, CFO, and you've plugged into the Photocure results for second quarter 2021.
Next slide. Just reminder, disclaimers are in fact for today's presentation. Next slide. Top line second quarter highlights. We've had progress in both commercial regions despite the continued pandemic, COVID-19. We had 66% revenue growth in the second quarter. That's 87% positive constant currency. EBITDA of positive NOK 5.8 million. We also had 3 key study publications. One of them actually emanating from our own U.S. registry, which is fantastic. And partnership activities continue with Asieris dosing the first patient for Cevira in Europe, [pivots] Phase III trial. And Genotests in Chile filed its MAA on a fast track review and expect more information as time goes on.
Next slide. I'd like to give you a really quick COVID-19 update. Access restrictions continued due to the third and fourth waves. We're now entering into the delta wave, unfortunately
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)